FMC Corporation Donates Personal Protective Equipment to Local Health Systems
PHILADELPHIA, March 27, 2020 –
FMC Corporation (NYSE: FMC) has donated nearly 165,000 masks to five major health systems in the Greater Philadelphia region to assist frontline healthcare workers during the COVID-19 pandemic. The recipient organizations include Penn Medicine, Jefferson Health, Children’s Hospital of Philadelphia, Temple University Health System, and ChristianaCare.
The company began to source additional personal protective equipment (PPE), which are used in FMC laboratories, greenhouses and production facilities, in January 2020 as COVID-19 emerged and started to spread in Asia and other regions.
"A review of our PPE at key FMC sites around the world revealed opportunities to redirect some of those materials to locations in critical need," said Pierre Brondeau, FMC chief executive officer and chairman. "Earlier this week, we received a delivery of 140,000 surgical masks, which have been donated to area health systems. An additional 24,500 N95 masks have also been donated. We offer our thanks to the men and women who are working on the front lines at area hospitals. All of us at FMC are keeping them in our thoughts during these extraordinary times."
FMC, an agricultural science company, employs approximately 800 at its global headquarters at FMC Tower in Philadelphia. The company also has more than 550 scientists and associates at its global R&D campus, the FMC Stine Research Center, in Newark, Delaware.
FMC Corporation, an agricultural sciences company, provides innovative solutions to growers around the world with a robust product portfolio fueled by a market-driven discovery and development pipeline in crop protection, plant health, and professional pest and turf management. This powerful combination of advanced technologies includes leading insect control products based on Rynaxypyr? and Cyazypyr? active ingredients; Authority?, Boral?, Centium?, Command? and Gamit? branded herbicides; Talstar? and Hero? branded insecticides; and flutriafol-based fungicides. The FMC portfolio also includes biologicals such as Quartzo? and Presence? bionematicides. FMC Corporation employs approximately 6,400 employees around the globe. To learn more, please visit www.bzyuium.buzz.
FMC, the FMC logo, Rynaxypyr, Cyazypyr, Authority, Boral, Centium, Command, Gamit, Talstar, Hero, Quartzo and Presence are trademarks of FMC Corporation or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. Hero? insecticide is a restricted use pesticide in the United States.
Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which are based on management's current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These factors include, among other things, the risk factors and other cautionary statements included within FMC's 2019 Form 10-K filed with the SEC as well as other SEC filings and public communications. FMC cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement. FMC undertakes no obligation, and specifically disclaims any duty, to update or revise any forward-looking statements to reflect events or circumstances arising after the date on which they were made, except as otherwise required by law.
SOURCE FMC Corporation
Media contact: Emily Parenteau, +1.215.299.6288, [email protected] | Investor contact: Michael Wherley, +1.215.299.6543, [email protected]